ES2187261B2 - Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos. - Google Patents

Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.

Info

Publication number
ES2187261B2
ES2187261B2 ES200100058A ES200100058A ES2187261B2 ES 2187261 B2 ES2187261 B2 ES 2187261B2 ES 200100058 A ES200100058 A ES 200100058A ES 200100058 A ES200100058 A ES 200100058A ES 2187261 B2 ES2187261 B2 ES 2187261B2
Authority
ES
Spain
Prior art keywords
preparation
compounds
eteres
amidas
diabetic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100058A
Other languages
English (en)
Other versions
ES2187261A1 (es
Inventor
Tsuyoshi Tomiyama
Akira Tomiyama
Hiroshi Tomiyama
Keiko Kuroiwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Original Assignee
Kotobuki Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Seiyaku Co Ltd filed Critical Kotobuki Seiyaku Co Ltd
Publication of ES2187261A1 publication Critical patent/ES2187261A1/es
Application granted granted Critical
Publication of ES2187261B2 publication Critical patent/ES2187261B2/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compuestos de éteres y amidas y su preparación, como agentes anti-diabéticos representados por la siguiente fórmula (I) y sus sales farmacéuticamente aceptables:
ES200100058A 2000-01-11 2001-01-10 Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos. Expired - Fee Related ES2187261B2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000006106 2000-01-11
JP12/6106 2000-01-11
JP2000356303A JP4316787B2 (ja) 2000-01-11 2000-11-22 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
JP12/356303 2000-11-22

Publications (2)

Publication Number Publication Date
ES2187261A1 ES2187261A1 (es) 2003-05-16
ES2187261B2 true ES2187261B2 (es) 2004-07-16

Family

ID=26583525

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100058A Expired - Fee Related ES2187261B2 (es) 2000-01-11 2001-01-10 Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.

Country Status (9)

Country Link
US (1) US6414001B2 (es)
JP (1) JP4316787B2 (es)
KR (1) KR20010070442A (es)
CN (1) CN1227231C (es)
DE (1) DE10100772B4 (es)
ES (1) ES2187261B2 (es)
FR (1) FR2804681B1 (es)
GB (1) GB2359082B (es)
IT (1) ITMI20010042A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016332A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
US6930120B2 (en) 2000-08-23 2005-08-16 Eli Lilly And Company Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
HUP0400091A2 (hu) * 2001-04-26 2004-06-28 Léciva, a.s. Eljárás antidiabetikus hatású pioglitazon előállítására
PL367077A1 (en) 2001-06-07 2005-02-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors (ppar)
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
TWI281916B (en) 2001-10-25 2007-06-01 Lilly Co Eli Antitumor compounds and methods
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US20080045706A1 (en) * 2002-12-31 2008-02-21 Flynn Daniel L Anti-inflammatory medicaments
US7202257B2 (en) * 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物
US7348453B2 (en) * 2003-09-04 2008-03-25 Mirus Bio Corporation Labile linkage for compound delivery to a cell
JP4175291B2 (ja) * 2004-05-12 2008-11-05 トヨタ自動車株式会社 車両の減速制御装置
DE102004039509B4 (de) * 2004-08-14 2006-09-21 Sanofi-Aventis Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DK1650186T3 (da) * 2004-10-22 2008-10-13 Sun Pharmaceutical Ind Ltd Nye dicarboxylsyrederivater
CN101735048A (zh) * 2008-11-05 2010-06-16 上海慈瑞医药科技有限公司 具胰岛素增敏活性的水杨酸类化合物及其制备方法
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
US10071957B2 (en) 2012-07-06 2018-09-11 Genentech, Inc. N-substituted benzamides and methods of use thereof
BR112015008987A2 (pt) 2012-10-26 2017-07-04 Merck Sharp & Dohme composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
CN112028833B (zh) * 2020-09-25 2022-07-05 西南大学 对氨基水杨酸唑类衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239080A (en) * 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217432B (hu) * 1988-03-08 2000-01-28 Pfizer Inc. Eljárás tiazolidin-dion-származékok és az ezeket tartalmazó gyógyszerkészítmények előállítására, a vegyületek és a készítmények
DK0544696T3 (da) * 1990-08-23 1995-06-06 Pfizer Hypoglycæmiske hydroxyurinstofderivater
TW245716B (es) * 1992-12-28 1995-04-21 Takeda Pharm Industry Co
TW268952B (es) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EE03765B1 (et) * 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
WO2001016111A2 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Hypoglycemic sulfonyl pyrazolones and pyrazolines
US6617343B1 (en) * 1999-08-27 2003-09-09 Eli Lilly And Company Hypoglycemic N,N-arylsulfonylglycine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239080A (en) * 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COBB, J.E. y col. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma Agonista. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent. J. Med. Chem., 1998, Vol. 41, páginas 5055-5069. Páginas 5062-5063, tablas 4,5. *
COLLINS, J.L. y col. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma Agonista. 2. Structure-Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety. J. Med. Chem., 1998, Vol. 41, páginas 5037-5054. Página 5038, columna 1; página 5041, tabla 1. *
HULIN, B. y col. Novel Thiazolidine-2,4-diones as Potent Euglycemic Agents. Journal of Medicinal Chemistry, 1992, Vol. 35, Nº 10, páginas 1853-1864, ISSN 0022-2623. Página 1858, tabla VII, ejemplos 63,66. *

Also Published As

Publication number Publication date
GB2359082A (en) 2001-08-15
GB2359082B (en) 2004-09-29
KR20010070442A (ko) 2001-07-25
ES2187261A1 (es) 2003-05-16
US6414001B2 (en) 2002-07-02
CN1315320A (zh) 2001-10-03
US20010008898A1 (en) 2001-07-19
GB0100433D0 (en) 2001-02-21
JP2001261662A (ja) 2001-09-26
DE10100772B4 (de) 2005-09-22
DE10100772A1 (de) 2001-07-19
JP4316787B2 (ja) 2009-08-19
ITMI20010042A1 (it) 2002-07-11
FR2804681B1 (fr) 2004-06-25
CN1227231C (zh) 2005-11-16
FR2804681A1 (fr) 2001-08-10

Similar Documents

Publication Publication Date Title
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
PT1379520E (pt) Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b
HRP20080664A2 (hr) Supstituirani piridinski herbicidi
ITRM20010464A1 (it) Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
DE60112974D1 (en) Carbolinderivate
HRP20060254A2 (en) Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
PA8527001A1 (es) Poliarilcarboxamidas utiles como agentes reductores de lipidos
DOP2002000433A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso
UY27571A1 (es) 2-tio-3, 5-diciano-4-fenil-6-aminopiridinas sustituidas y su uso
MA26905A1 (fr) Derives de phenylglycine.
DE60216233D1 (en) Carbolinderivate
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
DE60112960D1 (de) Kondensierte pyridoindolderivate
DK1330458T3 (da) N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
AR027575A1 (es) Benzoilciclohexenonas substituidas
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR199901017A2 (xx) B�cek ilac� terkibi.
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
AR027349A1 (es) Derivados de amidas heterociclicas
ATE491709T1 (de) Pyrrolidinohydrochinazoline
TR200100475T2 (tr) N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030516

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2187261B2

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20110223